🇺🇸 FDA
Patent

US 8163281

Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis

granted A61KA61K2039/505A61K31/351

Quick answer

US patent 8163281 (Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K2039/505, A61K31/351, A61K38/177, A61K45/06